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COMMENTARY
Future Prospects for Periodontal Bioengineering Using Growth Factors
William V. Giannobile,*† Scott J. Hollister,†‡ and Peter X. Ma†x
Polypeptide growth factors have demonstrated strong potential to repair defects associated with teeth and dental implants.
Over the past two decades, intense research efforts have led to the clinical development of several growth factors or biologic
agents, including bonemorphogenetic proteins, platelet-derived growth factor, fibroblast growth factors, and enamelmatrix pro-
teins. Several of these growth factors are now being used clinically for a variety of applications, such as the promotion of peri-
odontal regeneration, sinus floor augmentation, and root coverage procedures. Although clinical results have been promising
and growth factors add another dimension to clinical care, optimization of growth factor targeting approaches to periodontal
wounds remains a challenge. Enhancement of growth factor local application to improve bioavailability, bioactivity, and allow-
ance of three-dimensional reconstruction of complex anatomic defects is a goal. This article will highlight developments for
growth factor delivery to better stimulate the wound healing response for periodontal and bone regeneration in the maxillofacial
region. Clin Adv Periodontics 2011;1:88-94.
Key Words: Bone morphogenetic proteins; fibroblast growth factors; platelet-derived growth factor; regeneration;
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Current State-of-the-Art
This special issue highlights the current status of growth
factor technologies in the clinical arena. Regenerative
medicine and tissue-engineering innovations have greatly
advanced periodontology over the past decade.1 Several
key pivotal human clinical trials have led to the clinical
application of bone morphogenetic proteins (BMPs) for
localized alveolar ridge2 and for sinus floor augmenta-
tion.3 For platelet-derived growth factor (PDGF), it has
been used for periodontal regeneration4,5 and for the
promotion of root coverage.6 Most recently, fibroblast
growth factor-2 (FGF-2) has been evaluated in a large
human clinical trial for the promotion of periodontal
regeneration.7,8 As such, in this issue, Drs. Murakami
et al., Misch and Wang, and Kao and Lynch highlight in
greater detail not only the specific studies above but other
investigations that explore expanded indications of these
technologies for application in the clinical arena for oral
bone and soft-tissue repair (Table 1). In this perspective,
we will highlight several key areas of development that the
field is undertaking to better stimulate the wound healing
response for periodontal and bone regeneration in the
maxillofacial region.
Scaffolding Matrices to Enhance Growth
Factor Release to Periodontal and Bone
Defects
The use of scaffolding matrices to deliver growth factors to
promote periodontal tissue regeneration has been an active
area of research.9 Controlled release strategies were re-
cently characterized by Hubbell.10 He specifically charac-
terized controlled release strategies for tissue engineering
as 1) bioactive factors mixed with matrices; 2) bioactive
factors entrapped within gel matrices; 3) bioactive factors
entrapped within hydrophobic microparticles; 4) bioactive
factors bound to affinity sites within matrices, and 5) bio-
active factors covalently bound to matrices. Of these five
categories, only strategies 1, 4, and 5 present the potential
for a completely integrated structural delivery because cat-
egories 2 and 3 are non-load–bearing vehicles that must be
further fixed to a load-bearing structure. However, in the
case of periodontal wound repair in space-making defects,
the above may be an insignificant limitation. As an exam-
ple of strategy 2, Lutolf et al.11 used polyethylene glycol-
based hydrogels as BMP-2 delivery vehicles in critical sized
calvarial defects.
The major class of currently used BMP-2 delivery vehi-
cles fall into category 1, ‘‘bioactive factors mixed with
matrices.’’ The best known of these is the current Food
and Drug Administration–approved BMP-2 carrier bo-
vine type I collagen sponge12 that has been used clinically
(approved or off-label) for in-spine fusion,13-15 tibial non-
union repair,16 and multiple craniofacial applications, in-
cluding sinus lift, tooth socket repair, and cleft defects.2,3,17
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However, collagen sponges are suboptimal delivery devices
that often lead to uncontrolled bolus delivery of BMP-2,
which allows diffusion of the protein into surrounding
soft tissues. The presence of BMP-2 in soft tissues leads
to some patient complications, including dysphagia, air-
way compression in cervical spine fusion, and heterotopic
bone formation in the spinal canal.18-20
Alternative materials to collagen sponges have been
proposed. Schmidmaier et al.21,22 developed bioresorb-
able poly-(D, L)-lactic acid coatings for BMP-2 delivery
in which the BMP-2 was mixed in a thin film of polymer.
The release, as with collagen sponges, occurs when the
matrix degrades and polymer diffuses from the matrix.
They demonstrated significant increases in bone forma-
tion but also noted that z50% of growth factors using
this delivery approach were eluted during the first 48
hours. This fact illustrates the drawback of this (and
any) approach mixing biofactors with matrices, namely
that once the matrix begins degrading, there is limited
control over growth factor diffusion. As such, binding
of growth factors directly to biomaterials offers signifi-
cant potential (see below).
The simplest approach within Hubbell’s10 schema is to
bind BMP-2 to natural or enhanced affinity binding sites
on complex three-dimensional scaffold surfaces (category
4). This binding oftenoccurs through electrostatic charge in-
teractions between the protein and biomaterial surface. Rai
et al.23 described adsorption of BMP-2on three-dimensional
polycaprolactone (PCL) and PCL/tricalcium phosphate/
fibrin composite scaffolds made by fused deposition model-
ing. They also found that local BMP-2 retention rates on the
scaffolds ranged from z50% to 75% at 2 days, dropping
to z0% to 20% by 15 days.
The last category10 for controlled release is category 5,
‘‘bioactive factors covalently bound to matrices.’’ This
method provides the tightest binding of growth factors
to substrates and is useful to retain growth factors locally
as to avoid dispersion of BMPs into the soft tissues,
which can lead to ectopic bone formation.24 To date, there
have not been reports related to ectopic bone formation in
extraction sockets or in sinus floor elevation procedures.
In the periodontium, the use of these scaffold constructs
made of a variety of formulations, such as polymeric bio-
materials of polylactic glycolic acid (PLGA), PCL, or poly-
lactic acid, have been well studied.24 These materials have
been used extensively to deliver not only growth factors but
also genes and cells.25 Additionally, a variety of ceramic
biomaterials, such as hydroxyapatite, b-tricalcium phos-
phate, or other calcium phosphate ceramics, are being used
as space-making constructs to support the three-
dimensional stability of complex periodontal and peri-
implant wound sites. These constructs are being used for
growth factor incorporation to provide bolus, pulse, or
constant slow release of growth factors. Within the poly-
meric constructs, microspheres or nanospheres encap-
sulating growth factors, antibiotics, or other anabolic
agents are being used to optimize wound repair and regen-
eration (Fig. 1).26 More recently, the BMP/transforming
growth factor-b family member known to have a role in
skeletal and joint development, growth and differentiation
factor-5 (GDF-5), has demonstrated significant potential
in the regeneration of periodontal ligament (PDL) and
bone in vertical bone defects using PLGA and b-tricalcium
phosphate carriers.27-29 Advances in computer-aided design
computer-aided manufacturer technology over the years
coupled with the expanded use of cone beam computed
tomography for imaging three-dimensional structures
allows for the construction of anatomically corrected
scaffolds for intimate, highly accurate fitting to complex
topographies of bone30-32 and periodontal defects (Fig.
2).33 Wikesjö et al.34 have demonstrated that BMPs coated
onto titanium porous oxide implant surfaces of dental
implants allow for the release and subsequent acceleration
of osseointegration in alveolar ridge defects.










BMP-2 X X X
BMP-7 X X X
GDF-5 X X
FGF-2 X X X
PDGF-BB X X X
Preclinical Evidence and Clinical Evidence refer to periodontal applications.
FIGURE 1 Biomimetic nano-scaffold for application in periodontal bio-
engineering. The scaffold combines novel nano-fibrous architecture of an
interconnected pore network with microspheres for controlled release of
putative regenerative factors. The nano-fibrous scaffolding design uses the
architectural features of collagen, providing a high surface area for cell
attachment and new matrix deposition, and an open structure allowing an
interactive environment for cellcell, cellnutrient, and cellsignal molecule
interactions. The bone mineral mimicking apatite enhances osteoconductivity
of the scaffold. The biodegradable microspheres release the regenerative
factors in a controlled manner in a targeted local environment. Adapted with
permission from Elsevier (reference 26).
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Emerging Technologies for Gene and
Stem Cell Delivery Technologies to
Enhance Bioavailability of Growth Factors
The use of gene therapy offers significant potential to target
and deliver growth factor genes to periodontal defects.35,36
Gene delivery has been shown to increase bioavailabil-
ity, improve factor targeting to cells within osseous de-
fects, and improve the overall delivery of growth factors to
wounds in a more biologically relevant dose level compared
to the ‘‘dose-dumping’’ formulations generally used in top-
ical protein delivery of growth factors.37 Growth factors
such as PDGF have been used to repair periodontal38,39
and peri-implant40 bone defects, whereas BMPs have been
used to treat a wider range of craniofacial defects, includ-
ing the jaws, peri-implant defects,41 extraction sockets,
and periodontal lesions.42 The use of gene delivery technol-
ogies has shown potential in the clinical arena to stimulate
regeneration of chronic diabetic wounds in patients with
neuropathic defects.43,44 However, at this time, human
FIGURE 2 The reverse-engineered periodontal defect-fit scaffold modeling and the adaptation of customized designed scaffold on the root surface. 2a
Computer-aided design-based software (NX version 5 software, UGS, Plano, TX) was used to create PDL (red) and bone (blue) interfaces of the hybrid scaffold.
The anatomic defect-fit scaffold had the perpendicular-oriented PDL internal channel structures and topological similarities of the periodontal defects. The
furcation defect design had separated two different parts with a key (buccal)-lock (lingual) system to make easier assembling and implanting through the
buccallingual penetration defect region. The red line was the porcine mandible image with the customized scaffold, and the blue line was the exposed
periodontal defect site. 2b The histogram represented the 99.9% adaptable scaffold to the root surface. The measured length was 3.00 mm, and the scaffold
was coated by 35% BaSO4 solution. The yellow lines on the two-dimensionally digitized slices represented the measured regions with 3.00 mm length from the
dentin (dental pulp side) to the middle of defect site. AB ¼ alveolar bone; R ¼ tooth root; Sc ¼ hybrid scaffold. 2c The histogram was from 83.5% adaptable
scaffold image. The concaved region of the red line can represent the gap distance (dgap) between tooth root surface and PDL interface scaffold. 2d Based on
the method in 2c and 2d, total PDL interface length (dtotal) and dgap were linearly measured, and the adaptation ratio was calculated in each layer, which had
three different channel-type structures. There was no statistically significant difference (N.S.) among six different layers, and the range of adaptation was
83.3% < mean value of adaptation ratio < 99.0%, and data were mean – SD. For the statistical analysis, the non-parametric Kruskal-Wallis one-way analysis
of variance test was used. Reproduced with permission from Elsevier (reference 33).
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clinical data are not available for treatment of periodontal
defects, only early-stage preclinical safety assessments.38
Early studies for salivary gland repair have demonstrated
proof-of-concept in the craniofacial complex.45
The use of cell delivery approaches has been reviewed re-
cently for application to oral and periodontal wounds.25
It has been long known that the PDL offers significant
regenerative potential as a source of progenitor cells that
can regenerate periodontal wounds.46,47 The use of stem
cell transplantation of PDL progenitors has been demon-
strated in vivo in a variety of contexts.48,49 Although prom-
ising in the administration of cells as local factories to
drive production of newly formed tissues, the use of autol-
ogous cells for the repair of oral and periodontal wounds
is quite limited, primarily from a practical standpoint.50
However, the use of allogenic cell-delivery approaches
has demonstrated significant potential in several human
clinical trials to expand the zone of attached and kerati-
nized gingiva through the production of local growth fac-
tors at the wound site.51-54 A commercial product has been
developed that uses cadaver-derived allogenic stem cells for
application in local bone repair procedures.55 Recently, cell
transplantation of PDL progenitor cells has demonstrated
the potential to form hybrid ligamentimplant constructs
(Fig. 3).56,57 As such, there is significant potential for the
use of either stem cells or PDL progenitor cells to form both
soft and hard periodontal tissues in vivo. However, the
practical challenges of regulatory, consistent cell popula-
tions from patient-to-patient and time required for pro-
curement will be steps requiring significant optimization
before being ready for the clinical arena in a real way.
Perspective
The significant advances in regenerative medicine offers
some exciting opportunities for the reconstruction of com-
plex periodontal defects. The field has grown significantly
over the past decade, and the use of growth factors for
application to periodontal and oral bone wounds is
now a clinical reality. The future areas of development
remain in delivery strategies to target growth factors to
FIGURE 3 Cell-based therapies for the tissue engineering of teeth, periodontia, and dental implant interfaces. Reprinted with permission from Wiley-Blackwell
(reference 57).
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periodontal osseous defects. The use of optimized delivery
vehicles will work on controlling the release and improving
bioavailability (via improved scaffold designs, three-
dimensional customized scaffolds, and possibly gene tar-
geting). The use of stem or progenitor cells to improve cell
sourcing to form new tissues and vasculature offers sig-
nificant potential for robust tissue regeneration. These
and other approaches will require important collabora-
tions among biologists, engineers, and periodontal re-
searches in concert with regulatory agencies and leaders
to bring these new technologies to the chair-side and clin-
ical practice. n
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